{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T05:23:01Z","timestamp":1785129781172,"version":"3.55.0"},"reference-count":92,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,3,1]],"date-time":"2018-03-01T00:00:00Z","timestamp":1519862400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"SERB, Govt. of India","award":["SB\/SO\/HS-209\/2013"],"award-info":[{"award-number":["SB\/SO\/HS-209\/2013"]}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cytokine"],"published-print":{"date-parts":[[2018,3]]},"DOI":"10.1016\/j.cyto.2017.12.029","type":"journal-article","created":{"date-parts":[[2018,1,10]],"date-time":"2018-01-10T10:19:51Z","timestamp":1515579591000},"page":"77-82","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"special_numbering":"C","title":["IL-23\/IL-17 immune axis in Guillain Barr\u00e9 Syndrome: Exploring newer vistas for understanding pathobiology and therapeutic implications"],"prefix":"10.1016","volume":"103","author":[{"given":"Monojit","family":"Debnath","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madhu","family":"Nagappa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geetanjali","family":"Murari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arun B.","family":"Taly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.cyto.2017.12.029_b0005","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1097\/00019052-200110000-00009","article-title":"Epidemiology of the Guillain-Barre syndrome","volume":"14","author":"Govoni","year":"2001","journal-title":"Curr. Opin. Neurol."},{"issue":"Suppl 2","key":"10.1016\/j.cyto.2017.12.029_b0010","doi-asserted-by":"crossref","first-page":"S92","DOI":"10.1086\/513793","article-title":"Clinical and epidemiologic features of Guillain-Barre syndrome","volume":"176","author":"Hughes","year":"1997","journal-title":"J. Infect. Dis."},{"issue":"6","key":"10.1016\/j.cyto.2017.12.029_b0015","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1093\/aje\/153.6.610","article-title":"Incidence of Guillain-Barre syndrome following infection with Campylobacter jejuni","volume":"153","author":"McCarthy","year":"2001","journal-title":"Am. J. Epidemiol."},{"issue":"10027","key":"10.1016\/j.cyto.2017.12.029_b0020","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1016\/S0140-6736(16)00562-6","article-title":"Guillain-Barre Syndrome outbreak associated with Zika virus infection in French Polynesia: a case-control study","volume":"387","author":"Cao-Lormeau","year":"2016","journal-title":"Lancet"},{"issue":"Pt 10","key":"10.1016\/j.cyto.2017.12.029_b0025","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1093\/brain\/123.10.2171","article-title":"Haemophilus influenzae infection and Guillain-Barre syndrome","volume":"123","author":"Mori","year":"2000","journal-title":"Brain"},{"issue":"1","key":"10.1016\/j.cyto.2017.12.029_b0030","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1001\/jamaneurol.2016.3541","article-title":"Diagnostic challenges and clinical characteristics of hepatitis E Virus-associated Guillain-Barre Syndrome","volume":"74","author":"Stevens","year":"2017","journal-title":"JAMA Neurol."},{"issue":"2","key":"10.1016\/j.cyto.2017.12.029_b0035","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.it.2003.12.004","article-title":"The Guillain-Barre syndrome: a true case of molecular mimicry","volume":"25","author":"Ang","year":"2004","journal-title":"Trends Immunol."},{"issue":"2","key":"10.1016\/j.cyto.2017.12.029_b0040","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1212\/WNL.40.2.215","article-title":"T cell activation in Guillain-Barre syndrome and in MS: elevated serum levels of soluble IL-2 receptors","volume":"40","author":"Hartung","year":"1990","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.cyto.2017.12.029_b0045","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1007\/s00415-013-7145-2","article-title":"Immune cell subtyping in the cerebrospinal fluid of patients with neurological diseases","volume":"261","author":"Kowarik","year":"2014","journal-title":"J. Neurol."},{"issue":"4","key":"10.1016\/j.cyto.2017.12.029_b0050","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.jocn.2004.04.006","article-title":"Increased circulating T cell reactivity to GM1 ganglioside in patients with Guillain-Barre syndrome","volume":"12","author":"Csurhes","year":"2005","journal-title":"J. Clin. Neurosci."},{"issue":"4","key":"10.1016\/j.cyto.2017.12.029_b0055","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1177\/039463200902200420","article-title":"T cell response in acute motor axonal neuropathy","volume":"22","author":"Cencioni","year":"2009","journal-title":"Int. J. Immunopathol. Pharmacol."},{"issue":"2","key":"10.1016\/j.cyto.2017.12.029_b0060","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/0022-510X(92)90069-W","article-title":"T cell responses to myelin proteins in Guillain-Barre syndrome","volume":"111","author":"Khalili-Shirazi","year":"1992","journal-title":"J. Neurol. Sci."},{"issue":"Pt 9","key":"10.1016\/j.cyto.2017.12.029_b0065","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.1093\/brain\/awg207","article-title":"Distinct time pattern of complement activation and cytotoxic T cell response in Guillain-Barre syndrome","volume":"126","author":"Wanschitz","year":"2003","journal-title":"Brain"},{"issue":"5","key":"10.1016\/j.cyto.2017.12.029_b0070","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1002\/ana.410390512","article-title":"Immune attack on the Schwann cell surface in acute inflammatory demyelinating polyneuropathy","volume":"39","author":"Hafer-Macko","year":"1996","journal-title":"Ann. Neurol."},{"issue":"4","key":"10.1016\/j.cyto.2017.12.029_b0075","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/ni0407-345","article-title":"T(H)-17 cells in the circle of immunity and autoimmunity","volume":"8","author":"Bettelli","year":"2007","journal-title":"Nat. Immunol."},{"issue":"1\u20132","key":"10.1016\/j.cyto.2017.12.029_b0080","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.jns.2013.03.002","article-title":"Role of Th17 cells in the pathogenesis of CNS inflammatory demyelination","volume":"333","author":"Rostami","year":"2013","journal-title":"J. Neurol. Sci."},{"issue":"12","key":"10.1016\/j.cyto.2017.12.029_b0085","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1084\/jem.20030896","article-title":"Divergent pro- and antiinflammatory roles for IL-23 and IL-12 in joint autoimmune inflammation","volume":"198","author":"Murphy","year":"2003","journal-title":"J. Exp. Med."},{"issue":"9","key":"10.1016\/j.cyto.2017.12.029_b0090","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/nri3707","article-title":"The IL-23-IL-17 immune axis: from mechanisms to therapeutic testing","volume":"14","author":"Gaffen","year":"2014","journal-title":"Nat. Rev. Immunol."},{"issue":"19","key":"10.1016\/j.cyto.2017.12.029_b0095","doi-asserted-by":"crossref","first-page":"5823","DOI":"10.3748\/wjg.v21.i19.5823","article-title":"Contribution of the IL-17\/IL-23 axis to the pathogenesis of inflammatory bowel disease","volume":"21","author":"Catana","year":"2015","journal-title":"World J. Gastroenterol."},{"issue":"10","key":"10.1016\/j.cyto.2017.12.029_b0100","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1038\/nrrheum.2015.128","article-title":"The IL-23-IL-17 axis in inflammatory arthritis","volume":"11","author":"Lubberts","year":"2015","journal-title":"Nat. Rev. Rheumatol."},{"issue":"77","key":"10.1016\/j.cyto.2017.12.029_b0105","first-page":"253","article-title":"Role of the IL-23\/IL-17 axis in Crohn's disease","volume":"14","author":"Siakavellas","year":"2012","journal-title":"Discov. Med."},{"issue":"1","key":"10.1016\/j.cyto.2017.12.029_b0110","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1111\/cei.12670","article-title":"The interleukin (IL)-23\/IL-17 axis in ankylosing spondylitis: new advances and potentials for treatment","volume":"183","author":"Jethwa","year":"2016","journal-title":"Clin. Exp. Immunol."},{"issue":"1","key":"10.1016\/j.cyto.2017.12.029_b0115","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1007\/s10875-013-9965-3","article-title":"Increased circulating Th17 cell populations and elevated CSF osteopontin and IL-17 concentrations in patients with Guillain-Barre syndrome","volume":"34","author":"Han","year":"2014","journal-title":"J. Clin. Immunol."},{"key":"10.1016\/j.cyto.2017.12.029_b0120","doi-asserted-by":"crossref","first-page":"260473","DOI":"10.1155\/2012\/260473","article-title":"IL-17 and IL-22 in cerebrospinal fluid and plasma are elevated in Guillain-Barre syndrome","volume":"2012","author":"Li","year":"2012","journal-title":"Mediators Inflamm."},{"issue":"3","key":"10.1016\/j.cyto.2017.12.029_b0125","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1111\/sji.12201","article-title":"Mitigated Tregs and augmented Th17 cells and cytokines are associated with severity of experimental autoimmune neuritis","volume":"80","author":"Wang","year":"2014","journal-title":"Scand. J. Immunol."},{"issue":"2","key":"10.1016\/j.cyto.2017.12.029_b0130","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1517\/14728222.2016.1086751","article-title":"Are Th17 cells and their cytokines a therapeutic target in Guillain-Barre syndrome?","volume":"20","author":"Wu","year":"2016","journal-title":"Expert Opin. Ther. Targets"},{"key":"10.1016\/j.cyto.2017.12.029_b0135","doi-asserted-by":"crossref","first-page":"564098","DOI":"10.1155\/2015\/564098","article-title":"Biomarkers of Guillain-Barre Syndrome: some recent progress, more still to be explored","volume":"2015","author":"Wang","year":"2015","journal-title":"Mediators Inflamm."},{"issue":"5","key":"10.1016\/j.cyto.2017.12.029_b0140","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1038\/mi.2009.100","article-title":"Th17 cells at the crossroads of innate and adaptive immunity against infectious diseases at the mucosa","volume":"2","author":"Khader","year":"2009","journal-title":"Mucosal. Immunol."},{"issue":"8","key":"10.1016\/j.cyto.2017.12.029_b0145","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1038\/nri2586","article-title":"Structure and signalling in the IL-17 receptor family","volume":"9","author":"Gaffen","year":"2009","journal-title":"Nat. Rev. Immunol."},{"issue":"5","key":"10.1016\/j.cyto.2017.12.029_b0150","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1172\/JCI28508","article-title":"The IL-23\/IL-17 axis in inflammation","volume":"116","author":"Iwakura","year":"2006","journal-title":"J. Clin. Invest."},{"issue":"4","key":"10.1016\/j.cyto.2017.12.029_b0155","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.immuni.2004.08.018","article-title":"Interleukin-17 family members and inflammation","volume":"21","author":"Kolls","year":"2004","journal-title":"Immunity"},{"issue":"7198","key":"10.1016\/j.cyto.2017.12.029_b0160","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1038\/nature07036","article-title":"Induction and effector functions of T(H)17 cells","volume":"453","author":"Bettelli","year":"2008","journal-title":"Nature"},{"issue":"7090","key":"10.1016\/j.cyto.2017.12.029_b0165","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/nature04754","article-title":"Transforming growth factor-beta induces development of the T(H)17 lineage","volume":"441","author":"Mangan","year":"2006","journal-title":"Nature"},{"issue":"9","key":"10.1016\/j.cyto.2017.12.029_b0170","doi-asserted-by":"crossref","first-page":"5948","DOI":"10.4049\/jimmunol.181.9.5948","article-title":"IL-23 promotes maintenance but not commitment to the Th17 lineage","volume":"181","author":"Stritesky","year":"2008","journal-title":"J. Immunol."},{"issue":"7152","key":"10.1016\/j.cyto.2017.12.029_b0175","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1038\/nature05969","article-title":"Essential autocrine regulation by IL-21 in the generation of inflammatory T cells","volume":"448","author":"Nurieva","year":"2007","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.cyto.2017.12.029_b0180","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.immuni.2010.05.003","article-title":"Diverse targets of the transcription factor STAT3 contribute to T cell pathogenicity and homeostasis","volume":"32","author":"Durant","year":"2010","journal-title":"Immunity"},{"issue":"5","key":"10.1016\/j.cyto.2017.12.029_b0185","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/S1074-7613(00)00070-4","article-title":"Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12","volume":"13","author":"Oppmann","year":"2000","journal-title":"Immunity"},{"issue":"8","key":"10.1016\/j.cyto.2017.12.029_b0190","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1038\/ni.2366","article-title":"IL-12 family cytokines: immunological playmakers","volume":"13","author":"Vignali","year":"2012","journal-title":"Nat. Immunol."},{"issue":"6924","key":"10.1016\/j.cyto.2017.12.029_b0195","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1038\/nature01355","article-title":"Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain","volume":"421","author":"Cua","year":"2003","journal-title":"Nature"},{"issue":"7","key":"10.1016\/j.cyto.2017.12.029_b0200","doi-asserted-by":"crossref","first-page":"503","DOI":"10.3109\/07853890.2011.577093","article-title":"Interleukin-23: a key cytokine in inflammatory diseases","volume":"43","author":"Duvallet","year":"2011","journal-title":"Ann. Med."},{"issue":"9","key":"10.1016\/j.cyto.2017.12.029_b0205","doi-asserted-by":"crossref","first-page":"5296","DOI":"10.4049\/jimmunol.0900036","article-title":"IL-23 drives pathogenic IL-17-producing CD8+ T cells","volume":"182","author":"Ciric","year":"2009","journal-title":"J. Immunol."},{"issue":"12","key":"10.1016\/j.cyto.2017.12.029_b0210","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1038\/ni1539","article-title":"TGF-beta and IL-6 drive the production of IL-17 and IL-10 by T cells and restrain T(H)-17 cell-mediated pathology","volume":"8","author":"McGeachy","year":"2007","journal-title":"Nat. Immunol."},{"issue":"5","key":"10.1016\/j.cyto.2017.12.029_b0215","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1172\/JCI25308","article-title":"Anti-IL-23 therapy inhibits multiple inflammatory pathways and ameliorates autoimmune encephalomyelitis","volume":"116","author":"Chen","year":"2006","journal-title":"J. Clin. Invest."},{"issue":"2","key":"10.1016\/j.cyto.2017.12.029_b0220","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1084\/jem.20041257","article-title":"IL-23 drives a pathogenic T cell population that induces autoimmune inflammation","volume":"201","author":"Langrish","year":"2005","journal-title":"J. Exp. Med."},{"issue":"2","key":"10.1016\/j.cyto.2017.12.029_b0225","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1358\/dnp.2006.19.2.977443","article-title":"Pathophysiology of interleukin-23 in experimental autoimmune encephalomyelitis","volume":"19","author":"Touil","year":"2006","journal-title":"Drug News Perspect."},{"issue":"8","key":"10.1016\/j.cyto.2017.12.029_b0230","doi-asserted-by":"crossref","first-page":"e23185","DOI":"10.1371\/journal.pone.0023185","article-title":"IL-1 and IL-23 mediate early IL-17A production in pulmonary inflammation leading to late fibrosis","volume":"6","author":"Gasse","year":"2011","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.cyto.2017.12.029_b0235","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1074\/jbc.M207577200","article-title":"Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17","volume":"278","author":"Aggarwal","year":"2003","journal-title":"J. Biol. Chem."},{"issue":"6","key":"10.1016\/j.cyto.2017.12.029_b0240","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.3109\/08923973.2012.697469","article-title":"Th17 helper cell and T-cell immunoglobulin and mucin domain 3 involvement in Guillain-Barre syndrome","volume":"34","author":"Liang","year":"2012","journal-title":"Immunopharmacol. Immunotoxicol."},{"issue":"3","key":"10.1016\/j.cyto.2017.12.029_b0245","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.4049\/jimmunol.1502100","article-title":"Expression of early growth response gene-2 and regulated cytokines correlates with recovery from Guillain-Barre Syndrome","volume":"196","author":"Doncel-Perez","year":"2016","journal-title":"J. Immunol."},{"key":"10.1016\/j.cyto.2017.12.029_b0250","first-page":"1","article-title":"Polymorphisms of IL-17 and ICAM-1 and their expression in Guillain-Barre syndrome","author":"Kharwar","year":"2016","journal-title":"Int. J. Neurosci."},{"key":"10.1016\/j.cyto.2017.12.029_b0255","doi-asserted-by":"crossref","first-page":"639712","DOI":"10.1155\/2013\/639712","article-title":"Elevated levels of cerebrospinal fluid and plasma interleukin-37 in patients with Guillain-Barre syndrome","volume":"2013","author":"Li","year":"2013","journal-title":"Mediators Inflamm."},{"issue":"6","key":"10.1016\/j.cyto.2017.12.029_b0260","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1001\/archneur.63.6.858","article-title":"Interleukin 23 in acute inflammatory demyelination of the peripheral nerve","volume":"63","author":"Hu","year":"2006","journal-title":"Arch. Neurol."},{"issue":"2","key":"10.1016\/j.cyto.2017.12.029_b0265","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.expneurol.2006.03.014","article-title":"T cell infiltration after chronic constriction injury of mouse sciatic nerve is associated with interleukin-17 expression","volume":"200","author":"Kleinschnitz","year":"2006","journal-title":"Exp. Neurol."},{"issue":"3","key":"10.1016\/j.cyto.2017.12.029_b0270","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.jpain.2010.08.003","article-title":"Interleukin-17 contributes to neuroinflammation and neuropathic pain following peripheral nerve injury in mice","volume":"12","author":"Kim","year":"2011","journal-title":"J. Pain"},{"key":"10.1016\/j.cyto.2017.12.029_b0275","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/1742-2094-11-63","article-title":"Interleukin-17 impedes Schwann cell-mediated myelination","volume":"11","author":"Stettner","year":"2014","journal-title":"J. Neuroinflamm."},{"issue":"1","key":"10.1016\/j.cyto.2017.12.029_b0280","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1006\/exnr.2000.7357","article-title":"Enhancement of acute phase and inhibition of chronic phase of experimental autoimmune neuritis in Lewis rats by intranasal administration of recombinant mouse interleukin 17: potential immunoregulatory role","volume":"163","author":"Pelidou","year":"2000","journal-title":"Exp. Neurol."},{"issue":"1","key":"10.1016\/j.cyto.2017.12.029_b0285","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.cytogfr.2003.10.003","article-title":"Inducible nitric oxide synthase activation by interleukin-17","volume":"15","author":"Miljkovic","year":"2004","journal-title":"Cytokine Growth Factor Rev."},{"issue":"1","key":"10.1016\/j.cyto.2017.12.029_b0290","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.bbrc.2015.12.093","article-title":"IL-17A up-regulates expression of endothelial tissue factor in liver cirrhosis via the ROS\/p38 signal pathway","volume":"470","author":"Pu","year":"2016","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"7","key":"10.1016\/j.cyto.2017.12.029_b0295","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1038\/nm.2391","article-title":"Identification of an innate T helper type 17 response to intestinal bacterial pathogens","volume":"17","author":"Geddes","year":"2011","journal-title":"Nat. Med."},{"issue":"6086","key":"10.1016\/j.cyto.2017.12.029_b0300","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1126\/science.1223490","article-title":"Interactions between the microbiota and the immune system","volume":"336","author":"Hooper","year":"2012","journal-title":"Science"},{"issue":"11","key":"10.1016\/j.cyto.2017.12.029_b0305","doi-asserted-by":"crossref","first-page":"e15398","DOI":"10.1371\/journal.pone.0015398","article-title":"Delineation of the innate and adaptive T-cell immune outcome in the human host in response to Campylobacter jejuni infection","volume":"5","author":"Edwards","year":"2010","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.cyto.2017.12.029_b0310","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1002\/mus.20105","article-title":"Blood gammadelta T cells, Campylobacter jejuni, and GM1 titers in Guillain-Barre syndrome","volume":"30","author":"Scelsa","year":"2004","journal-title":"Muscle Nerve"},{"issue":"3","key":"10.1016\/j.cyto.2017.12.029_b0315","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1093\/intimm\/dxg041","article-title":"Expansion of human gammadelta T cells after in vitro stimulation with Campylobacter jejuni","volume":"15","author":"Van Rhijn","year":"2003","journal-title":"Int. Immunol."},{"issue":"1","key":"10.1016\/j.cyto.2017.12.029_b0320","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1046\/j.1365-2249.1997.4221318.x","article-title":"Stimulation of peripheral blood lymphocytes with Campylobacter jejuni generates a gammadelta T cell response in patients with Guillain-Barresyndrome","volume":"109","author":"Ben-Smith","year":"1997","journal-title":"Clin. Exp. Immunol."},{"issue":"2","key":"10.1016\/j.cyto.2017.12.029_b0325","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1556\/1886.2016.00008","article-title":"The role of IL-23, IL-22, and IL-18 in Campylobacter jejuni infection of conventional infant mice","volume":"6","author":"Heimesaat","year":"2016","journal-title":"Eur. J. Microbiol. Immunol. (Bp)"},{"issue":"3","key":"10.1016\/j.cyto.2017.12.029_b0330","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1007\/s00430-015-0445-7","article-title":"Cytokine kinetics of Zika virus-infected patients from acute to reconvalescent phase","volume":"205","author":"Tappe","year":"2016","journal-title":"Med. Microbiol. Immunol."},{"issue":"4","key":"10.1016\/j.cyto.2017.12.029_b0335","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.autrev.2017.02.002","article-title":"Autoimmunity in Guillain-Barre syndrome associated with Zika virus infection and beyond","volume":"16","author":"Pinto-Diaz","year":"2017","journal-title":"Autoimmun. Rev."},{"issue":"6","key":"10.1016\/j.cyto.2017.12.029_b0340","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1212\/WNL.37.6.1006","article-title":"Guillain-Barre syndrome: activated complement components C3a and C5a in CSF","volume":"37","author":"Hartung","year":"1987","journal-title":"Neurology"},{"issue":"5","key":"10.1016\/j.cyto.2017.12.029_b0345","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1172\/JCI113231","article-title":"Activation of terminal components of complement in patients with Guillain-Barre syndrome and other demyelinating neuropathies","volume":"80","author":"Koski","year":"1987","journal-title":"J. Clin. Invest."},{"issue":"6","key":"10.1016\/j.cyto.2017.12.029_b0350","doi-asserted-by":"crossref","first-page":"4211","DOI":"10.4049\/jimmunol.177.6.4211","article-title":"Mannose-binding lectin contributes to the severity of Guillain-Barre syndrome","volume":"177","author":"Geleijns","year":"2006","journal-title":"J. Immunol."},{"issue":"5","key":"10.1016\/j.cyto.2017.12.029_b0355","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1182\/blood-2009-01-198283","article-title":"Complement promotes the development of inflammatory T-helper 17 cells through synergistic interaction with Toll-like receptor signaling and interleukin-6 production","volume":"114","author":"Fang","year":"2009","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.cyto.2017.12.029_b0360","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1084\/jem.20092301","article-title":"Complement drives Th17 cell differentiation and triggers autoimmune arthritis","volume":"207","author":"Hashimoto","year":"2010","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.cyto.2017.12.029_b0365","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1479-5876-9-111","article-title":"Complement component C5a promotes expression of IL-22 and IL-17 from human T cells and its implication in age-related macular degeneration","volume":"9","author":"Liu","year":"2011","journal-title":"J. Transl. Med."},{"issue":"10","key":"10.1016\/j.cyto.2017.12.029_b0370","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1038\/ni.1926","article-title":"Complement-mediated regulation of the IL-17A axis is a central genetic determinant of the severity of experimental allergic asthma","volume":"11","author":"Lajoie","year":"2010","journal-title":"Nat. Immunol."},{"issue":"2","key":"10.1016\/j.cyto.2017.12.029_b0375","doi-asserted-by":"crossref","first-page":"159","DOI":"10.2174\/187152812800392805","article-title":"The IL23\/Th17 pathway as a therapeutic target in chronic inflammatory diseases","volume":"11","author":"Toussirot","year":"2012","journal-title":"Inflamm. Allergy Drug Targets"},{"issue":"2","key":"10.1016\/j.cyto.2017.12.029_b0380","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1111\/j.1365-2567.2011.03522.x","article-title":"Interleukin-23: as a drug target for autoimmune inflammatory diseases","volume":"135","author":"Tang","year":"2012","journal-title":"Immunology"},{"issue":"3","key":"10.1016\/j.cyto.2017.12.029_b0385","doi-asserted-by":"crossref","first-page":"216","DOI":"10.4161\/mabs.1.3.8593","article-title":"Ustekinumab","volume":"1","author":"Cingoz","year":"2009","journal-title":"MAbs"},{"issue":"2","key":"10.1016\/j.cyto.2017.12.029_b0390","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1124\/jpet.115.224246","article-title":"Dual inhibition of interleukin-23 and interleukin-17 offers superior efficacy in mouse models of autoimmunity","volume":"354","author":"Mangan","year":"2015","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"2","key":"10.1016\/j.cyto.2017.12.029_b0395","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.cellimm.2011.08.015","article-title":"Atorvastatin ameliorates experimental autoimmune neuritis by decreased Th1\/Th17 cytokines and up-regulated T regulatory cells","volume":"271","author":"Li","year":"2011","journal-title":"Cell. Immunol."},{"issue":"1\u20132","key":"10.1016\/j.cyto.2017.12.029_b0400","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.jneuroim.2014.02.002","article-title":"Therapeutic potential of atorvastatin-modified dendritic cells in experimental autoimmune neuritis by decreased Th1\/Th17 cytokines and up-regulated T regulatory cells and NKR-P1(+) cells","volume":"269","author":"Xu","year":"2014","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.cyto.2017.12.029_b0405","article-title":"PR-957, a selective inhibitor of immunoproteasome subunit low-MW polypeptide 7, attenuates experimental autoimmune neuritis by suppressing Th17 cell differentiation and regulating cytokine production","author":"Liu","year":"2017","journal-title":"FASEB J."},{"issue":"1","key":"10.1016\/j.cyto.2017.12.029_b0410","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1186\/s12974-016-0559-x","article-title":"Dimethyl fumarate attenuates experimental autoimmune neuritis through the nuclear factor erythroid-derived 2-related factor 2\/hemoxygenase-1 pathway by altering the balance of M1\/M2 macrophages","volume":"13","author":"Han","year":"2016","journal-title":"J. Neuroinflamm."},{"key":"10.1016\/j.cyto.2017.12.029_b0415","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1186\/s12883-014-0202-3","article-title":"Changes in lymphocyte subsets in patients with Guillain-Barre syndrome treated with immunoglobulin","volume":"14","author":"Hou","year":"2014","journal-title":"BMC Neurol."},{"issue":"2\u20133","key":"10.1016\/j.cyto.2017.12.029_b0420","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1007\/s12026-014-8580-6","article-title":"Intravenous immunoglobulin exerts reciprocal regulation of Th1\/Th17 cells and regulatory T cells in Guillain-Barre syndrome patients","volume":"60","author":"Maddur","year":"2014","journal-title":"Immunol. Res."},{"issue":"5","key":"10.1016\/j.cyto.2017.12.029_b0425","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1038\/cmi.2014.117","article-title":"Intravenous immunoglobulin-mediated expansion of regulatory T cells in autoimmune patients is associated with increased prostaglandin E2 levels in the circulation","volume":"12","author":"Maddur","year":"2015","journal-title":"Cell. Mol. Immunol."},{"issue":"1","key":"10.1016\/j.cyto.2017.12.029_b0430","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s12974-017-0818-5","article-title":"Regulatory T cell frequency, but not plasma IL-33 levels, represents potential immunological biomarker to predict clinical response to intravenous immunoglobulin therapy","volume":"14","author":"Maddur","year":"2017","journal-title":"J. Neuroinflamm."},{"key":"10.1016\/j.cyto.2017.12.029_b0435","doi-asserted-by":"crossref","first-page":"740947","DOI":"10.1155\/2014\/740947","article-title":"Circulating Th17, Th22, and Th1 cells are elevated in the Guillain-Barre syndrome and downregulated by IVIg treatments","volume":"2014","author":"Li","year":"2014","journal-title":"Mediators Inflamm."},{"issue":"1\u20132","key":"10.1016\/j.cyto.2017.12.029_b0440","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.jneuroim.2007.09.034","article-title":"Abnormality of circulating CD4(+)CD25(+) regulatory T cell in patients with Guillain-Barre syndrome","volume":"192","author":"Chi","year":"2007","journal-title":"J. Neuroimmunol."},{"issue":"1\u20132","key":"10.1016\/j.cyto.2017.12.029_b0445","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.jneuroim.2006.12.002","article-title":"Reduced circulating CD4+CD25+ cell populations in Guillain-Barre syndrome","volume":"183","author":"Pritchard","year":"2007","journal-title":"J. Neuroimmunol."},{"issue":"9","key":"10.1016\/j.cyto.2017.12.029_b0450","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/j.jocn.2007.09.016","article-title":"Increased levels of activated T-cells and reduced levels of CD4\/CD25+ cells in peripheral blood of Guillain-Barre syndrome patients compared to controls","volume":"15","author":"Harness","year":"2008","journal-title":"J. Clin. Neurosci."},{"issue":"10","key":"10.1016\/j.cyto.2017.12.029_b0455","first-page":"19126","article-title":"Expression and significance of CD4(+)CD25(+)CD127(-) regulatory T cells in peripheral blood of patients with different phenotypes of Guillain-Barre syndrome","volume":"8","author":"Wang","year":"2015","journal-title":"Int. J. Clin. Exp. Med."},{"key":"10.1016\/j.cyto.2017.12.029_b0460","doi-asserted-by":"crossref","first-page":"20963","DOI":"10.1038\/srep20963","article-title":"Circulating memory T follicular helper subsets, Tfh2 and Tfh17, participate in the pathogenesis of Guillain-Barre syndrome","volume":"6","author":"Che","year":"2016","journal-title":"Sci. Rep."}],"container-title":["Cytokine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043466617304003?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043466617304003?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,8,24]],"date-time":"2018-08-24T19:52:34Z","timestamp":1535140354000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043466617304003"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3]]},"references-count":92,"alternative-id":["S1043466617304003"],"URL":"https:\/\/doi.org\/10.1016\/j.cyto.2017.12.029","relation":{},"ISSN":["1043-4666"],"issn-type":[{"value":"1043-4666","type":"print"}],"subject":[],"published":{"date-parts":[[2018,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"IL-23\/IL-17 immune axis in Guillain Barr\u00e9 Syndrome: Exploring newer vistas for understanding pathobiology and therapeutic implications","name":"articletitle","label":"Article Title"},{"value":"Cytokine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cyto.2017.12.029","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}